We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
China’s FDA is threatening to severely punish companies that illegally manufacturer and sell codeine in the country, a warning the follows several revelations of the product was being sold in bulk quantities. Read More
Generic drug prices in Canada have fallen significantly in recent years, even while they continue to trend higher than their international cohorts, says a new Canadian government report. Read More
The FDA has approved Eli Lilly’s Cyramza to treat the most common type of lung cancer, the latest effort by the drugmaker to vastly increase uses of the oncology drug. Read More
A federal judge has ordered Actavis to keep the original version of its blockbuster Alzheimer’s therapy Namenda on the market while the court hears an ongoing antitrust lawsuit that claims the drugmaker wants to pull the older version to hinder generic competition. Read More
For the first time, a brand drugmaker has defeated a generics firm’s patent challenge through the U.S. Patent and Trademark Office’s internal review board process, which started in 2012. Read More
A large public employer has filed a federal class-action lawsuit accusing Gilead Sciences of price gouging with its $1,000-a-pill hepatitis C drug Sovaldi. Read More
A coalition of pharma companies and medical researchers is proposing a framework for determining authorship of clinical trial publications, with the aim of increasing transparency and public trust in medical research. Read More
Pharma companies today spend on average $2.6 billion to get new products to market, a 145 percent increase in R&D costs compared with a decade ago, the Tufts Center for the Study of Drug Development reports. Read More
A federal judge has paved the way for generic entry of Cubist’s antibiotic Cubicin by 2016 after striking down four out of five patents challenged by Hospira. Read More
Pfizer’s blockbuster arthritis pain drug Celebrex is facing generic competition for the first time after Teva, Mylan and Actavis launched versions Wednesday. Read More